Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Pulsar Helium Shows Positive Seismic Survey Results for Upcoming Appraisal Well (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Vanda Pharmaceuticals Inc VNDA

Healthcare Biotechnology
Vanda Pharmaceuticals Inc. (Vanda) is a global biopharmaceutical company focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Vanda's commercial portfolio is comprised of two products, HETLIOZ for the treatment of jet lag disorder, insomnia, delayed sleep phase disorder (DSPD), sleep disturbances in autism spectrum... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:VNDA)

Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis

PR Newswire 1 day ago

Vanda Pharmaceuticals Announces Participation at November 2023 Investor Conferences

PR Newswire November 9, 2023

Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results

PR Newswire November 8, 2023

Vanda Pharmaceuticals to Announce Third Quarter 2023 Financial Results on November 8, 2023

PR Newswire November 1, 2023

Vanda Pharmaceuticals Intends to Petition the U.S. Supreme Court in its HETLIOZ® ANDA Litigation

PR Newswire October 20, 2023

Vanda Pharmaceuticals Announces Participation in the Jefferies Inaugural Biotech CNS/Neuro Summit

PR Newswire October 5, 2023

Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference

PR Newswire September 6, 2023

Vanda Pharmaceuticals Reports Second Quarter 2023 Financial Results

PR Newswire July 27, 2023

Vanda Pharmaceuticals to Announce Second Quarter 2023 Financial Results on July 27, 2023

PR Newswire July 20, 2023
View More News ››

Opinion & Analysis (NDAQ:VNDA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:VNDA)

$VNDA -Settlement

$VNDA -On May 19, 2022, Vanda Pharmaceuticals agreed to settle a securities fraud class action complaint (the “Complaint”) for $11.5...
JGrabar - May 31, 2022

RE: RE: i guess many MISSED this one ??LOL

So did I ..... I missed Vanda's run WOW &excl; I also hold a Jr Pharma named Pharmagap Inc.I&CloseCurlyQuote;m a shareholder...
bullorbear22 - July 5, 2009

RE: i guess many MISSED this one ??LOL

It's not too late - buy some now.  Haha just kidding, don't feel bad I missed it too.
jjwilson - May 7, 2009

Consensus target at $40

Three analysts have 12-mo. price targets on this company with a consensus view of around $40 ($35, $40, and $44), yet now it seems to...
moneystud - March 14, 2007
View more Bullboard ››

Hank Payments Corp.

Hank Payments Corp.

Hank Payments is a North American leader in consumer Fintech Software-as-a-Service (“SaaS”) in the Banking-as-a-Service ...
View More »